None
Quote | Command Security Corporation (NYSE:MOC)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $2.845 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Command Security Corporation (NYSE:MOC)
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...
Message Board Posts | Command Security Corporation (NYSE:MOC)
Subject | By | Source | When |
---|---|---|---|
I hope this sale provides some additional contracts. | cj 13 | investorshub | 09/20/2018 1:04:35 AM |
* * $MOC Video Chart 08-02-18 * * | ClayTrader | investorshub | 08/02/2018 9:34:56 PM |
MOC share price looks like it's trying to | cj 13 | investorshub | 03/09/2018 3:12:29 PM |
29 percent year to year. Think the next | cj 13 | investorshub | 06/19/2017 5:50:21 PM |
I agree. I am definitely going to buy | Cboneofenglewood | investorshub | 06/18/2017 3:39:27 AM |
News, Short Squeeze, Breakout and More Instantly...
Command Security Corporation Company Name:
MOC Stock Symbol:
NYSE Market:
Command Security Corporation Website:
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's first administration of a chitotriosidase 1...
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will take a daily oral dose of 25 mg OATD-01 or...
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or “The Company”) announces part of the results of the work program consisting of eight drill holes for a total of 2,484 meters on the Gaboury project . Highlig...